Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports

International Journal of Eating Disorders

Volumn 44, Issue 3, 2011, Pages 269-275

  Trunko, Mary Ellen ^a   Schwartz, Terry A ^a   Duvvuri, Vikas ^a   Kaye, Walter H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anorexia nervosa; Aripiprazole; Atypical antipsychotics; Bulimia nervosa; Dopamine; Long term follow up

Indexed keywords

ARIPIPRAZOLE;

ADULT; ANOREXIA NERVOSA; ANXIETY; ARTICLE; BODY IMAGE; BODY MASS; BODY WEIGHT; BULIMIA; CASE REPORT; CLINICAL FEATURE; COGNITION; DEPRESSION; FEMALE; FOOD; HUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REMISSION;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BULIMIA NERVOSA; FEMALE; HUMANS; MIDDLE AGED; PIPERAZINES; QUINOLONES; TREATMENT OUTCOME;

EID: 79952669299     PISSN: 02763478     EISSN: 1098108X     Source Type: Journal    
DOI: 10.1002/eat.20807     Document Type: Article

References (40)

1. Barbarich N, McConaha C, Gaskill J, LaVia M, Frank GK, Achenbach S, et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004;65:1480-1482.
2. Bosanac P, Burrows G, Norman T. Olanzapine in anorexia nervosa. Aust NZ J Psychiatry 2003;37:494.
3. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, et al. Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol 2007;22:197-204. (Pubitemid 46801942)
4. Dennis K, Le Grange D, Bremer J. Olanzapine use in adolescent anorexia nervosa. Eat Weight Disord 2006;11:e53-e56. (Pubitemid 44049711)
5. Ercan E, Copkunol H, Cykoethlu S, Varan A. Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol 2003;18:401-403. (Pubitemid 36896426)
6. Mondraty N, Birmingham C, Touyz SW, Sundakov V, Chapman L, Beaumont P. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005;13:72-75. (Pubitemid 40514990)
7. Wang T, Chou Y, Shiah I. Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:306-309. (Pubitemid 43288072)
8. Boachie A, Goldfield G, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: Case reports. Int J Eat Disord 2003;33:98-103. (Pubitemid 36020247)
9. Jensen VS, Mejlhede A. Anorexia nervosa: Treatment with olanzapine. Br J Psychiatry 2000;177:87.
10. Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, Kaye WH. Olanzapine treatment of anorexia nervosa: A restrospective study. Int J Eat Disord 2003;33:234-237. (Pubitemid 36249838)
11. Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann RW. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry 2001;10:151-157. (Pubitemid 32612154)
12. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: An open label trial. Int J Eat Disord 2002;32:146-154. (Pubitemid 34848184)
13. Hansen L. Olanzapine in the treatment of anorexia nervosa. Br J Psychiatry 1999;175:592.
14. La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000;27:363-366. (Pubitemid 30160017)
15. Bosanac P, Kurlender S, Norman T, Hallam K, Wesnes K, Manktelow T, Burrows G. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007;22:223-230. (Pubitemid 46939279)
16. Mehler-Wex C, Romanos M, Kirchheiner J, Schulze U. Atypical antipsychotics in severe anorexia nervosa in children and adolescents-review and case reports. Eur Eat Disord Rev 2008;16:100-108. (Pubitemid 351566271)
17. Powers P, Bannon Y, Eubanks R, McCormick T. Quetiapine in anorexia nervosa patients: An open label outpatient pilot study. Int J Eat Disord 2007;40:21-26. (Pubitemid 44936523)
18. Fisman S, Steele M, Short J, Byrne T, Lavallee C. Case study: Anorexia nervosa and autistic disorder in an adolescent girl. J Am Acad Child Adolsc Psychiatry 1996;35:937-940. (Pubitemid 26230929)
19. Newman-Toker J. Risperidone in anorexia nervosa. J Am Acad Child Adolesc Psychiatry 2000;39:941-942.
20. Bissada H, Tasca G, Barber A, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008;165:1281-1288.
21. Halmi K. The perplexities of conducting randomized, double-blind, placebo-controlled treatment trials in anorexia nervosa patients. Am J Psychiatry 2008;165:1227-1228.
22. Aragona M. Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure. Eat Weight Disord 2007;12:e54-e57. (Pubitemid 351398835)
23. Henderson D. Weight gain with atypical antipsychotics: Evidence and insights. J Clin Psychiatry 2007;68(Suppl 12):18-26. (Pubitemid 350021619)
24. Newcomer J. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93. (Pubitemid 40677047)
25. Brewerton T, Shannon M. Possible clozapine exacerbation of bulimia nervosa. Am J Psychiatry 1992;149:1408-1409.
26. Gebhardt S, Haberhausen M, Krieg J, Remschmidt H, Heinzel-Gutenbrunner M, Hebebrand J, et al. Clozapine/olanzapineinduced recurrence or deterioration of binge eating-related eating disorders. J Neural Transm 2007;114:1091-1095. (Pubitemid 47106444)
27. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier P, et al. Clozapine and olanzapine are associated with food craving and binge eating: Results from a randomized double-blind study. J Clin Psychopharm 2007;27:662-666. (Pubitemid 351339453)
28. Theisen F, Linden A, König IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003;110:111-121. (Pubitemid 36135558)
29. Crockford D, Fisher G, Barker P. Risperidone, weight gain, and bulimia nervosa. Can J Psychiatry 1997;42:326-327. (Pubitemid 27257135)
30. Wagner A, Barbarich N, Frank G, Bailer U, Weissfeld L, Henry S, et al. Personality traits after recovery from eating disorders: Do subtypes differ? Int J Eat Disord 2006;39:276-284.
31. Hoffman E, Mathew S. Anxiety disorders: A comprehensive review of pharmacotherapies. Mt Sinai J Med 2008;75:248-262.
32. Philip N, Carpenter L, Tyrka A, Price L. Augmentation of anti-depressants with atypical antipsychotics: A review of the current literature. J Psychiatr Pract 2008;14:34-44. (Pubitemid 351158846)
33. Ohlsen R, Pilowsky L. The place of partial agonism in psychiatry: recent developments. J Psychopharmacol 2005;19:408-413. (Pubitemid 41003138)
34. Pae C, Serretti A, Patkar A, Masand P. Aripiprazole in the treatment of depressive and anxiety disorders: A review of current evidence. CNS Drugs 2008;22:367-388. (Pubitemid 351508122)
35. Haddad P, Sharma S. Adverse effects of atypical antipsychotics: Differential risk and clinical implications. CNS Drugs 2007;21:911-936. (Pubitemid 47557106)
36. Sharif Z. Side effects as influencers of treatment outcome. J Clin Psychiatry 2008;69(Suppl 3):38-43.
37. Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008;94:121-135. (Pubitemid 351506510)
38. Kaye W, Frank G, Bailer U, Henry S. The neurobiology of anorexia nervosa: Clinical implications of alterations of the function of serotonin and other neuronal systems. Int J Eat Disord 2005;37:S15-S19; Discussion S20-S21; Special Issue on Anorexia Nervosa.
39. DeLeon A, Patel N, Crismon M. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26:649-666. (Pubitemid 38736956)
40. Seroquel (quetiapine). Full Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2008.